INVESTIGATION OF MUTATIONS AND EXPRESSION OF THE FHIT GENE IN TURKISH PATIENTS WITH BRAIN METASTASES DERIVED FROM NON-SMALL CELL LUNG CANCER

Ahmet Bekar¹, Gülşah Çeçener², Berrin Tunca³, Gulnur Guler³, Unal Egeli², and Şahsine Tolunay⁴

¹Department of Neurosurgery, ²Department of Medical Biology, Faculty of Medicine, Uludag University, Bursa; ³Department of Pathology, Faculty of Medicine, Hacettepe University, Ankara; ⁴Department of Pathology, Faculty of Medicine, Uludag University, Bursa, Turkey

Aims and background: Brain metastases occur in 20-40% of patients with cancer, and their frequency has increased over time. Lung, breast and skin (melanoma) are the most common sources of brain metastases. Recent studies show that several genes such as CD44 and PTEN have roles in the suppression of metastatic growth. Although it has been determined that there is a relationship between the FHIT gene and several primary tumors, its role in the initiation and progression of brain tumors has not yet been entirely explained. Furthermore, it is not known whether the FHIT gene has a role in the formation of brain metastases.

Patients and methods: The present study investigated mutations of the FHIT gene in Turkish patients with brain metastases derived from non-small cell lung cancer (NSCLC). Single-strand conformational polymorphism and sequencing analysis of the coding exons (5-9) of the FHIT gene were performed on 26 tissues. Furthermore, the level of Fhit protein expression of 36 tumor tissues was identified by immunohistochemistry.

Results: Using single-strand conformational polymorphism and sequencing analyses, no point mutations of the FHIT gene were detected in brain metastases derived from NSCLC. However, it was observed that Fhit protein expression was reduced in 88.9% of subjects.

Conclusions: We suggest that the FHIT gene may be turned off in brain metastases via other genetic/epigenetic mechanisms rather than mutations.

Key words: brain metastases, FHIT gene, immunohistochemistry, NSCLC, point mutations.

Acknowledgments: We would like to thank to Prof Dr Kay Huebner from Ohio State University for kindly providing Fhit antisera and Prizma and Elips Ltd. for their support in dealing with experimental equipment.

Correspondence to: Dr Ahmet Bekar, Department of Neurosurgery, Faculty of Medicine, Uludag University, Bursa-Turkey.
Tel +90 224 2952700; fax +90 224 4429263; e-mail abekar@uludag.edu.tr

Received January 15, 2007; accepted July 10, 2007.